GlucoRx and Cardiff University are set to bring out the world’s first multi-sensor non-invasive continuous glucose monitor (CGM) to herald a new era of needle-free monitoring for people with diabetes.
The GlucoRx BioXensor™ uses patented radio frequency technology alongside a multiple sensor approach to measure blood glucose levels every minute reliably, accurately, and non-invasively.
According to the World Health Organization, approximately 422 million people around the globe have diabetes.
Currently, people with diabetes have to painfully prick their finger to extract and test their blood several times a day using glucometers or apply semi-invasive devices such as continuous blood glucose monitors (CGMs).
The GlucoRx BioXensor™ now provides people with a painless, accurate, sustainable, and cost-effective alternative to blood glucose monitoring for the first time by measuring levels from 3 mmol/l to 30 mmol/l.
When used as an early intervention to change lifestyle, the GlucoRx BioXensor™ will assist in preventing the onset of diabetes, or its remission, and improve quality of life with its smart alarms and remote monitoring technology.
Chris Chapman, GlucoRx Chief Operating Officer, said: “We are exciting about this life-changing end-to-end diabetes monitoring platform of ours which can be discreetly stuck on the skin to monitor blood glucose, giving readings every minute on smart mobile applications.
“GlucoRx BioXensor™ has standout accuracy owing to its multi sensor approach capturing blood glucose as well as Sp02, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection. The wearable device has a longer shelf-life because it is not chemical in its action.”
This work was supported by the Wellcome Trust and Cardiff University through its Cardiff Partnership Fund. Dr Heungjae Choi was funded by the Sêr Cymru II Fellowship by the European Regional Development Fund through the Welsh government.
Following a series of successful trials on early generation prototypes which achieved MARD of 10.4% at Swansea University with Professor Stephen Luzio, the team is now said to conduct a further pivotal clinical study later this year on its smaller and improved fourth generation device before submitting CE certification.